1. |
Rudd ML, Price JC, Fogoros S, et al. A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas. Clin Cancer Res, 2011, 17(6):1331-1340.
|
2. |
Miron A, Varadi M, Carrasco D, et al. PIK3CA mutations in in situ and invasive breast carcinomas. Cancer Res, 2010, 70(14):5674-5678.
|
3. |
Barbareschi M, Buttitta F, Felicioni L, et al. Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. Clin Cancer Res, 2007, 13(20):6064-6269.
|
4. |
王平,耿小平,朱立新, 等. 肝细胞肝癌中外周血浆DNA基因甲基化检测及意义. 中国普外基础与临床杂志, 2012, 19(7):727-732.
|
5. |
Murugan AK, Hong NT, Fukui Y, et al. Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas. Int J Oncol, 2008, 32(1):101-111.
|
6. |
Lee JW, Soung YH, Kim SY, et al. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene, 2005, 24(8):1477-1480.
|
7. |
Dunlap J, Le C, Shukla A, et al. Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma. Breast Cancer Res Treat, 2010, 120(2):409-418.
|
8. |
Li H, Zhu R, Wang L, et al. PIK3CA mutations mostly begin to develop in uctal carcinoma of the breast. Exp Mol Pathol, 2010, 88(1):150-155.
|
9. |
MacConaill LE, Campbell CD, Kehoe SM, et al. Profiling critical cancer gene mutations in clinical tumor samples. PLoS One, 2009, 4(11):e7887.
|
10. |
Fumagalli D, Gavin PG, Taniyama Y, et al. A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes. BMC Cancer, 2010, 10:101.
|
11. |
Kalinsky K, Jacks LM, Heguy A, et al. PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res, 2009, 15(16):5049-5059.
|
12. |
Campbell IG, Russell SE, Choong DY, et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res, 2004, 64(21):7678-7681.
|
13. |
Hayes MP, Douglas W, Ellenson LH. Molecular alterations of EGFR and PIK3CA in uterine serous carcinoma. Gynecol Oncol, 2009, 113(3):370-373.
|
14. |
Catasus L, Gallardo A, Cuatrecasas M, et al. Concomitant PI3KAKT and p53 alterations in endometrial carcinomas are associated with poor prognosis. Mod Pathol, 2009, 22(4):522-529.
|
15. |
Oda K, Okada J, Timmerman L, et al. PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation. Cancer Res, 2008, 68(19):8127-8136.
|
16. |
Dutt A, Salvesen HB, Chen TH, et al. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci U S A, 2008, 105(25):8713-8717.
|
17. |
Mandelker D, Gabelli SB, Schmidt-Kittler O, et al. A frequent kinase domain mutation that changes the interaction between PI3Kalpha and the membrane. Proc Natl Acad Sci U S A, 2009, 106(40):16996-17001.
|
18. |
Kang S, Bader AG, Vogt PK. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci U S A, 2005, 102(3):802-807.
|
19. |
Gymnopoulos M, Elsliger MA, Vogt PK. Rare cancer-specific mutations in PIK3CA show gain of function. Proc Natl Acad Sci U S A, 2007, 104(13):5569-5574.
|
20. |
Shoji K, Oda K, Nakagawa S, et al. The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas. Br J Cancer, 2009, 101(1):145-148.
|